In the DREAM clinical trial, 18,990 men and women, from 21 countries, were screened for entry. All had clinical and biochemical information collected at baseline, including an oral glucose tolerance test (OGTT), and were prospectively followed over a median (IQR) of 3.5 (3.0-4.0) years for incident cardiovascular (CV) events including coronary artery disease (CAD), stroke, congestive heart failure (CHF) requiring hospitalization, and death.

Primary endpoint:

Diabetes and cardiovascular disease.

In this large multi-ethnic cohort, the risk of cardiovascular events or death increased progressively among individuals who were normoglycaemic, IFG or IGT, and newly diagnosed diabetics. A 1 mmol/l increase in FPG was associated with a 17% increase in the risk of future CV events or death.

Therapeutic or behavioural interventions designed to either prevent glucose levels from rising, or lower glucose among individuals with dysglycaemia should be evaluated.

Study Type


Study Design

Cohort study

NO. of Countries


NO. of Sites


NO. of Participants


Study Period

2001 - 2008



Back To Top